CN110917307A - External-use water aqua for treating verruca plantaris and preparation method thereof - Google Patents
External-use water aqua for treating verruca plantaris and preparation method thereof Download PDFInfo
- Publication number
- CN110917307A CN110917307A CN201911361356.7A CN201911361356A CN110917307A CN 110917307 A CN110917307 A CN 110917307A CN 201911361356 A CN201911361356 A CN 201911361356A CN 110917307 A CN110917307 A CN 110917307A
- Authority
- CN
- China
- Prior art keywords
- parts
- lotion
- external
- traditional chinese
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 201000004303 plantar wart Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 44
- 239000006210 lotion Substances 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 20
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 17
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 17
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 17
- 241001071917 Lithospermum Species 0.000 claims abstract description 17
- UOHPEWIBMAQKCN-UHFFFAOYSA-N 1,3,5,5,6-pentafluoro-1,3-diazinane-2,4-dione Chemical group FC1C(C(N(C(N1F)=O)F)=O)(F)F UOHPEWIBMAQKCN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 241000334160 Isatis Species 0.000 claims abstract description 15
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 241000218691 Cupressaceae Species 0.000 claims abstract description 11
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 8
- 201000010153 skin papilloma Diseases 0.000 claims description 29
- 241000213006 Angelica dahurica Species 0.000 claims description 14
- 241001506766 Xanthium Species 0.000 claims description 14
- 241000246044 Sophora flavescens Species 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 6
- 241000212948 Cnidium Species 0.000 claims description 4
- 244000150195 Cyperus longus Species 0.000 claims description 4
- 241000219784 Sophora Species 0.000 claims description 4
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 claims description 3
- 235000008216 herbs Nutrition 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000013011 aqueous formulation Substances 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 2
- 235000018109 Cyperus longus Nutrition 0.000 claims 1
- 244000075634 Cyperus rotundus Species 0.000 claims 1
- 235000005010 Scirpus paludosus Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 11
- 231100000331 toxic Toxicity 0.000 abstract description 10
- 230000002588 toxic effect Effects 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 230000000451 tissue damage Effects 0.000 abstract description 3
- 231100000827 tissue damage Toxicity 0.000 abstract description 3
- 244000067505 Xanthium strumarium Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000000260 Warts Diseases 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 241000972673 Phellodendron amurense Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 2
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 239000010231 banlangen Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000000315 cryotherapy Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- WKZGKZQVLRQTCT-ABLWVSNPSA-N (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-formyloxy-5-oxopentanoic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(=O)OC=O)C(O)=O)C=C1 WKZGKZQVLRQTCT-ABLWVSNPSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000125175 Angelica Species 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005372 Blood blister Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010042344 Subcutaneous emphysema Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-L dUMP(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, and discloses an external-use liquid for treating plantar wart, which comprises an A lotion prepared from pure traditional Chinese medicines and a B external-use smearing liquid applied to an affected part, wherein the A lotion comprises the following raw material medicines: lithospermum, raw coix seeds, isatis roots, radix sophorae flavescentis, golden cypress, folium isatidis, safflower, rhizoma cyperi, equisetum hiemale, fructus cnidii, cocklebur fruits and radix angelicae; the B external application smearing water agent is a pentafluorouracil solution with the solubility of 5-10%. The lotion A is prepared from pure traditional Chinese medicines, has scientific and reasonable formula, simple preparation and no toxic or side effect, can effectively treat the plantar wart by being matched with the external smearing water aqua B, has no skin tissue damage in the treatment process, does not influence the daily life of a patient, and has quick recovery, no residue and no relapse.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to an external water aqua for treating verruca plantaris and a preparation method thereof.
Background
Warts are caused by Human Papillomavirus (HPV) infection, with an incidence of 13.1% accounting for 50% of the total HPV infection. Plantar wart occurs on the sole of the foot, and pain or extrusion pain can be caused at special parts, so that pain and inconvenience are brought to patients, and the influence is large. In the field of warts and warts in traditional Chinese medicine, the warts are considered to be formed by long-term friction on soles, insufficient endowment, insufficient striae, pathogenic wind attacking skin, or exuberant liver fire, stagnation of qi and blood, and vein dispergation, or due to liver blood deficiency, exogenesis of muscle and qi, and stagnation of qi and blood. Trauma and friction can be the cause of the disease, and hyperhidrosis in the foot is also related to the occurrence of plantar wart.
Plantar warts are more difficult to treat than common warts, and the methods for treating plantar warts are numerous. The whole body has long course of treatment, the curative effect is difficult to be determined, and the adverse reaction of the medicine is large. Common treatment methods are:
1. local physical therapy such as cryotherapy, fulgery, laser therapy or surgical resection, among others, wherein: the cryotherapy has adverse reactions such as pain, edema, blister or blood blister, subcutaneous emphysema, systemic reaction, hemorrhage, secondary infection, depigmentation, pigmentation, chronic ulcer, scar formation, nerve injury, etc.; the electric cautery therapy, the laser therapy or the surgical excision have large trauma to the injured part, the local repair time is long, the inconvenience is brought to the life of the patient, the secondary infection is easy, the patient with the scar constitution is forbidden to use, the treatment is not thorough, the recurrence is easy, permanent scars or recurrence can be caused, and the use is not suitable; the pelma skin has large elasticity and much movement, and the scar tissue has no elasticity, so that the drawing pain which cannot be treated can be caused during movement, and the long-term pain is brought to the patient;
2. chemical corrosive drugs such as phtalamine, tretinoin, 0.7% cantharidin and the like can also be used, but the drugs are not easy to absorb due to verruca plantaris surface keratosis, and the curative effect is poor;
3. topical bleomycin is also used for treatment of plantar warts and the like.
The above treatment methods mostly have local tissue damage, and the intact skin and mucosa are natural barriers for virus defense, and lactic acid in skin sweat, fat in sebum and lysozyme in mucosa secretion have the functions of preventing virus invasion and killing virus. It is critical that treatment of plantar warts maintain normal tissue intact and avoid damage to surrounding tissues.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: aiming at the defects of treating the plantar wart in the prior art, the external water aqua for treating the plantar wart and the preparation method thereof are provided, the external water aqua can keep the integrity of normal tissues and avoid damaging surrounding tissues, and has good treatment effect.
In order to solve the technical problems, the technical scheme provided by the invention is as follows:
an external-use water aqua for treating verruca plantaris comprises a lotion A prepared from pure traditional Chinese medicines, wherein the lotion A comprises the following raw material medicines:
lithospermum, raw coix seeds, isatis roots, lightyellow sophora roots, golden cypress, indigowoad leaves, safflower, nutgrass galingale rhizome, common scouring rush herbs, common cnidium fruits, cocklebur fruits and dahurian angelica roots.
Further, the externally applied liquid preparation B is applied to an affected part and is a pentafluorouracil solution with the solubility of 5% -10%.
Further, the B external application water aqua is a 5% solubility pentafluorouracil solution.
Further, the dosage of the raw materials of the lotion A is as follows:
20-50 parts of lithospermum, 30-70 parts of raw coix seeds, 30-70 parts of isatis roots, 10-30 parts of sophora flavescens, 10-30 parts of golden cypress, 30-70 parts of folium isatidis, 6-20 parts of safflower carthamus, 20-50 parts of rhizoma cyperi, 30-70 parts of equisetum hiemale, 15-40 parts of fructus cnidii, 15-40 parts of cocklebur fruits and 12-30 parts of angelica dahurica.
Further, the dosage of the raw materials of the lotion A is as follows:
40 parts of lithospermum, 60 parts of raw coix seeds, 60 parts of isatis roots, 20 parts of sophora flavescens, 20 parts of golden cypress, 60 parts of folium isatidis, 12 parts of safflower, 40 parts of rhizoma cyperi, 60 parts of equisetum hiemale, 30 parts of fructus cnidii, 30 parts of cocklebur fruits and 24 parts of angelica dahurica.
The invention also provides a preparation method of the external water aqua for treating plantar wart, which comprises the following steps:
1) decocting: putting the raw materials into a special medicinal bag for decoction, soaking in clear water for 30 minutes, putting into a traditional Chinese medicine decocting machine, adding 1000ml of clear water, and decocting at 110 deg.C for 1 hr;
2) subpackaging: taking out the medicine bag after the decoction is finished, and subpackaging and plastic-sealing the decocted liquid medicine in the traditional Chinese medicine decocting machine according to 200 ml/bag.
The pharmacology of each raw material medicine of the invention is as follows:
lithospermum: [ PROPERTIES AND FLAVOUR ] bitter and cold in taste. [ GUIJING ] returning to the heart, enveloping and regulating the liver meridian. Expect blood, promoting blood circulation, clearing away heat and toxic materials. It can be used for treating warm heat macula, damp-heat jaundice, purpura, emesis, epistaxis, hematuria, stranguria with turbid urine, constipation due to heat accumulation, burn, eczema, erysipelas, and carbuncle.
Raw coix seeds: [ PROPERTIES AND FLAVOUR ] sweet, bland and slightly cold. [ GUIJING ] can enter spleen, lung and kidney meridians. [ FUNCTIONS AND INDICATIONS ] can remove dampness, invigorate spleen, relax muscles and tendons, relieve arthralgia, clear heat and relieve distension. Can be used for treating edema, loempe, dribbling urination, diarrhea, leukorrhagia, rheumatalgia, spasm of tendons and vessels, pulmonary abscess, intestinal abscess, and verruca plana.
Radix isatidis: [ PROPERTIES AND FLAVOUR ] bitter and cold in taste. [ GUIJING ] enters liver and stomach meridians. [ FUNCTIONS AND INDICATIONS ] can clear away heat and toxic materials, cool blood and relieve sore throat. Can be used for treating toxic heat, speckle, hyperpyrexia, headache, epidemic headache, throat ulcer, erysipelas, itching cheek, pharyngitis, and sore.
Flavescent sophora root: [ PROPERTIES AND FLAVOUR ] bitter in taste and cold in nature. [ GUIJING ] GUIJING is responsible for the heart, liver, stomach, large intestine and bladder meridians. [ FUNCTIONS AND INDICATIONS ] can clear away heat, eliminate dampness, kill parasites and induce diuresis. Can be used for treating dysentery with heat, hematochezia, jaundice, anuria, leucorrhea with red and white discharge, pudendal swelling, pudendal pruritus, eczema, skin pruritus, scabies, tinea, leprosy, and trichomonas vaginitis.
Phellodendron bark: [ PROPERTIES AND FLAVOUR ] bitter in taste and cold in nature. [ GUIJING ] enters kidney and bladder meridians. [ FUNCTIONS AND INDICATIONS ] has effects of clearing heat, eliminating dampness, purging pathogenic fire, removing dampness, removing toxic substance, and treating sore. Can be used for treating damp-heat dysentery, jaundice, dark urine, leukorrhagia, pudendal pruritus, pyretic stranguria, pain, tinea pedis, asthenia, bone-steaming, overstrain, night sweat, spermatorrhea, pyocutaneous disease, toxic swelling, eczema, sore, and cortex Phellodendri. Can be used for treating hyperactivity of fire due to yin deficiency, night sweat and steaming bone.
Folium isatidis: [ PROPERTIES AND FLAVOUR ] bitter and cold in taste. [ GUIJING ] enters liver, heart, stomach and spleen meridians. [ FUNCTIONS AND INDICATIONS ] can clear away heat and toxic materials, cool blood and remove ecchymoses. Can be used for treating fever, polydipsia, unconsciousness, macula, hematemesis, epistaxis, jaundice, dysentery, etc.
Safflower: [ PROPERTIES AND FLAVOUR ] pungent and warm. [ GUIJING ] returning to the heart and liver meridians. [ FUNCTIONS AND INDICATIONS ] can promote blood circulation, dredge meridians, dispel blood stasis, and relieve pain. It can be used for treating amenorrhea due to blood stasis, thoracic obstruction, cardiodynia, abdominal mass, and arthralgia.
Rhizoma cyperi: [ PROPERTIES AND WESTERPHIS ] is pungent, slightly bitter, slightly sweet and mild. [ GUIJING ] enters liver, spleen and triple energizer meridians. [ FUNCTIONS AND INDICATIONS ] can soothe the liver, relieve depression, regulate qi, relieve epigastric distention, regulate menstruation and relieve pain. Can be used for treating stagnation of qi due to depression of the liver, distending pain in chest and hypochondrium, hernia pain, breast pain, stagnation of qi in spleen and stomach, abdominal distention, fullness and pain, menoxenia, amenorrhea, and dysmenorrhea.
B, horsetail: [ PROPERTIES AND FLAVOUR ] is sweet, bitter and neutral. [ GUIJING ] enters lung, liver and gallbladder meridians. [ FUNCTIONS AND INDICATIONS ] can dispel wind, dispel heat, relieve muscles and remove nebula. It is indicated for nebula, lacrimation in the wind, intestinal wind, bloody flux, liver failure, malaria, laryngalgia, carbuncle and swelling.
Fructus cnidii: [ PROPERTIES AND WESTERN PROPERTIES ] is pungent, bitter and warm; has little toxicity. [ GUIJING ] enters kidney meridian. [ FUNCTIONS AND INDICATIONS ] can warm kidney, strengthen yang, eliminate dampness, dispel wind, and kill parasites. Can be used for treating sexual impotence, cold womb, leukorrhagia due to cold-dampness, lumbago due to damp arthralgia, vulval eczema, pudendal pruritus, and trichomonas vaginitis.
Fructus xanthil: [ PROPERTIES AND WESTERN PROPERTIES ] with bitter, sweet, pungent and warm properties; and (5) small toxicity. [ GUIJING ] enters lung and liver meridians. [ FUNCTIONS AND INDICATIONS ] can dispel pathogenic wind and cold; clearing nasal orifices; dispelling wind-damp; relieving itching. Nasosinusitis; headache due to wind-cold evil; rheumatic arthralgia; rubella; eczema; scabies and tinea.
Radix angelicae: [ PROPERTIES AND WESTERN ] is warm in nature, pungent in flavor, fragrant in smell and slightly bitter. [ GUIJING ] enters lung, spleen and stomach meridians. [ FUNCTIONS AND INDICATIONS ] can dispel wind-damp, promote blood circulation, expel pus, promote granulation, and alleviate pain. Can be used for treating headache, toothache, nasosinusitis, hemorrhoid, leucorrhea with red and white discharge, carbuncle, cellulitis, pyocutaneous disease, and skin pruritus.
While the main ingredient of the topical liniment B, namely, pentafluorouracil (5-FU), inhibits DNA synthesis by inhibiting thymidylate synthase. The action of this enzyme may transfer one carbon unit of formyltetrahydrofolate to deoxyuridine-phosphate to synthesize thymidine monophosphate. Pentafluorouracil also has a certain inhibitory effect on RNA synthesis, and can destroy the replication and synthesis of tumor cells. The same principle can be used to stop the hyperproliferation of epithelial cells to form a keratinized state for the treatment of plantar warts.
The lithospermum and the safflower of the lotion A have the functions of promoting blood circulation by removing blood stasis, detoxifying and promoting eruption; radix Isatidis, folium Isatidis, and cortex Phellodendri can clear away heat and toxic materials; the sophora flavescens and the coix seeds remove dampness and toxin; the nutgrass galingale rhizome, the common scouring rush herb, the common cnidium fruit and the siberian cocklebur fruit regulate qi and relieve depression, and dispel wind and heat; the angelica dahurica granulation promoting and pain relieving effects are achieved by combining various medicines, have the effects of clearing heat and removing toxicity, promoting blood circulation to remove blood stasis, removing dampness and promoting granulation and pain relieving, promote wart dissipation and have obvious effect by matching with the B external application water aqua-pentafluorouracil solution.
In addition, in recent research reports, warm water foot bath is also shown to promote the migration, migration and maturation of Langerhans Cells (LC) at the virus infection part and the apoptosis of keratinocyte cells, soften the stratum corneum, promote the direct contact of liquid medicine and the affected part and promote the rapid absorption of the medicine.
The practical method of the invention comprises the following steps: after feet are cleaned, adding about 2000ml of warm water into a bag of lotion A, uniformly mixing and soaking feet for 20-30 minutes, wiping the mixture dry, and then wiping the mixture on the affected part with external application water aqua B once a day; a treatment course is 30-45 days.
Compared with the prior art, the invention has the advantages that:
the lotion A is prepared from pure traditional Chinese medicines, has scientific and reasonable formula, simple preparation and no toxic or side effect, can effectively treat plantar wart by being matched with an external smearing water aqua B, has no skin tissue damage in the treatment process, does not influence the daily life of a patient, and has the advantages of quick recovery, no residue and no relapse.
Detailed Description
The present invention is described in detail below for the purpose of better understanding technical solutions of the present invention by those skilled in the art, and the description of the present invention is only exemplary and explanatory and should not be construed as limiting the scope of the present invention in any way.
The invention provides an external water aqua for treating verruca plantaris, which comprises lotion A prepared from pure traditional Chinese medicines, and comprises the following raw material medicines:
lithospermum, raw coix seeds, isatis roots, lightyellow sophora roots, golden cypress, indigowoad leaves, safflower, nutgrass galingale rhizome, common scouring rush herbs, common cnidium fruits, cocklebur fruits and dahurian angelica roots.
The raw materials are used in the following weight portions:
20-50 parts of lithospermum, 30-70 parts of raw coix seeds, 30-70 parts of isatis roots, 10-30 parts of sophora flavescens, 10-30 parts of golden cypress, 30-70 parts of folium isatidis, 6-20 parts of safflower carthamus, 20-50 parts of rhizoma cyperi, 30-70 parts of equisetum hiemale, 15-40 parts of fructus cnidii, 15-40 parts of cocklebur fruits and 12-30 parts of angelica dahurica.
The external application liquid for treating plantar wart also comprises an external application liquid B applied to an affected part, wherein the external application liquid B is a pentafluorouracil solution with the solubility of 5-10%, and preferably 5%.
The invention also provides a preparation method of the external water aqua for treating plantar wart, which comprises the following steps:
1) decocting: putting the raw materials into a special medicinal bag for decoction, soaking in clear water for 30 minutes, putting into a traditional Chinese medicine decocting machine, adding 1000ml of clear water, and decocting at 110 deg.C for 1 hr;
2) subpackaging: taking out the medicine bag after the decoction is finished, and subpackaging and plastic-sealing the decocted liquid medicine in the traditional Chinese medicine decocting machine according to 200 ml/bag.
The present invention will be described in further detail with reference to the following examples:
example 1
Taking 20g of lithospermum, 30g of raw coix seeds, 30g of isatis roots, 10g of sophora flavescens, 10g of phellodendron barks, 30g of folium isatidis, 6g of safflower, 20g of rhizoma cyperi, 30g of equisetum hiemale, 15g of fructus cnidii, 15g of cocklebur fruits and 12g of angelica dahurica, mixing, putting into a special medicine bag for decoction, soaking in clear water for 30 minutes, putting into a traditional Chinese medicine decocting machine, adding 1000ml of clear water, decocting at the temperature of 110 ℃ for 1 hour to obtain an A lotion with the crude drug concentration of about 0.3g/ml, and subpackaging according to 200 ml/bag.
Wherein the concentration of crude drug is (the dosage of crude drug (g) -the dry weight of residue (g))/the volume of liquid medicine (ml).
Example 2
Mixing 30g of lithospermum, 45g of raw coix seeds, 45g of isatis roots, 15g of sophora flavescens, 15g of phellodendron barks, 45g of folium isatidis, 9g of safflower, 30g of rhizoma cyperi, 55g of equisetum hiemale, 25g of fructus cnidii, 20g of cocklebur fruits and 16g of angelica dahurica, and preparing the lotion A with the crude drug concentration of about 0.37g/ml according to the preparation method of the embodiment 1.
Example 3
Mixing 40g of lithospermum, 60g of raw coix seeds, 60g of isatis roots, 20g of sophora flavescens, 20g of phellodendron barks, 60g of folium isatidis, 12g of safflower, 40g of rhizoma cyperi, 60g of equisetum hiemale, 30g of fructus cnidii, 30g of cocklebur fruits and 24g of angelica dahurica, and preparing the lotion A with the crude drug concentration of about 0.45g/ml according to the preparation method of the embodiment 1.
Example 4
Taking 50g of lithospermum, 70g of raw coix seeds, 70g of isatis roots, 30g of sophora flavescens, 30g of phellodendron barks, 70g of folium isatidis, 20g of safflower, 50g of rhizoma cyperi, 70g of equisetum hiemale, 40g of fructus cnidii, 40g of cocklebur fruits and 30g of angelica dahurica, mixing, and obtaining the lotion A with crude drug concentration of about 0.6g/ml according to the preparation method of the embodiment 1.
It should be noted that, the traditional Chinese medicine decocting machine adopted in the above embodiment has an automatic water replenishing function, and performs automatic water replenishing according to the liquid level change in the monitoring decocting process, so as to ensure that the volume of the liquid medicine in the traditional Chinese medicine decocting machine is constant, and the automatic water replenishing belongs to the conventional prior art, for example: liquid level monitoring is carried out by adopting a liquid level sensor, and water is supplemented into the traditional Chinese medicine decocting machine by adopting a PLC (programmable logic controller) controlled pump.
Respectively using the lotion A prepared in the examples 1-4 to wash and soak the affected parts of a plurality of patients with plantar warts, adding about 2000ml of warm water into one bag of the lotion A, uniformly mixing and soaking feet for 20-30 minutes, controlling the temperature of the warm water at 40-45 ℃, wiping the mixture dry, and then smearing the affected parts with 5% of a pentafluorouracil solution once a day; a treatment course is 30-45 days.
Comparing the therapeutic effects of the specific applications of examples 1 to 4, the actual therapeutic effect of example 1 is generally better than that of example 1, the actual therapeutic effect of example 2 is better than that of example 1, the actual therapeutic effects of examples 3 and 4 are the best, and the doses of the raw materials of example 4 are higher than those of examples 3 and 4, but the effects are equivalent to those of example 3, and in conclusion, example 3 is the best example.
It should be noted that, because the external side effect of the traditional Chinese medicine is small, mainly depends on skin absorption, theoretically, the larger the dosage of each Chinese herbal medicine component contained in the lotion A is, the better the treatment effect is, but the chemical components contained in the traditional Chinese medicine are very complex, not only contain various effective components, but also have ineffective components and also contain toxic components, and because the absorption and recovery capability of the affected part is limited, each Chinese herbal medicine component is too much and also can cause unnecessary waste, and by combining the comparison of the above embodiments 1 to 4, through repeated clinical tests, the optimal dosage ratio of each raw material medicine can be obtained as follows:
40 parts of lithospermum, 60 parts of raw coix seeds, 60 parts of isatis roots, 20 parts of sophora flavescens, 20 parts of golden cypress, 60 parts of folium isatidis, 12 parts of safflower, 40 parts of rhizoma cyperi, 60 parts of equisetum hiemale, 30 parts of fructus cnidii, 30 parts of cocklebur fruits and 24 parts of angelica dahurica.
The dosage of the pentafluorouracil in the externally applied liniment is approximate to the toxic dosage, skin tissues also have the effect of absorbing the medicine into blood, the externally applied recommended solubility dosage is 5-10 percent usually, the treatment effect is not obvious when the concentration is too low, the side effect is large when the concentration is too high, the pentafluorouracil can be properly adjusted according to the actual condition of a patient in practical application, and the concentration of the pentafluorouracil solution is preferably 5 percent through repeated clinical tests, so that the treatment effect is optimal.
26 patients with plantar wart are clinically observed by the external-use water aqua, and the clinical report is as follows:
1. general data
The 26 patients who participated in the statistics were all from the outpatient clinic of this hospital, 12 men and 14 women. The age is 17-57 years, the average age is 32.2 years, the course of disease is 30 days-6 years, and the average age is 7 months.
2. Diagnostic criteria
Case observation: the skin damage is 2-9 cm, yellow or grey-brown papules are polluted at a single sole part or multiple parts of the soles of the toes, the surface is rough and ultra, black spots are formed in the center, the fusion is increased, the texture is hard, and the relevant standards of clinical dermatology are met.
3. Method of treatment
3.1 prescription:
and (A) lotion: 40g of lithospermum, 60g of raw coix seeds, 60g of isatis roots, 20g of sophora flavescens, 20g of golden cypress, 60g of folium isatidis, 12g of safflower, 40g of rhizoma cyperi, 60g of equisetum hiemale, 30g of fructus cnidii, 30g of cocklebur fruits and 24g of angelica roots.
B, external application smearing preparation: 5% strength pentafluorouracil solution.
3.2 the preparation method comprises the following steps: mixing the above raw materials, decocting with water (common Chinese medicinal preparation available in pharmacy), and packaging in 200 ml/bag.
3.3 methods of use: 1 bag each time, 1 time each time, and 20-30 minutes each time, wherein the water temperature is 50 ℃, 5% of pentafluorouracil solution is smeared on an affected part after wiping dry, and 30-45 days is a treatment course.
4. Therapeutic effects
4.1 treatment criteria:
the wart body completely falls off, and the patient without relapse is healed in the follow-up period;
more than 70% of warts fall off, and the effect is obvious when the volume is obviously reduced;
more than 30% of warts fall off, and the warts are effective when the volume is reduced;
the wart is not effective when less than 30% of the wart falls off and the volume is not obviously reduced.
4.2 results
The disease is cured by 23 cases (88.5 percent), improved by 3 cases (11.5 percent) and not cured by 0 case (0 percent). The total effective rate is 100 percent according to the cure plus improvement.
5. Typical cases
Case one:
wu, a certain woman, 22 years old, Shayangxian county, guan.
Diagnosis and treatment time: 2016, 7, 23 months.
The medical history: the plantar region and the inner side of the thumb of the right foot of the patient are scattered in a plurality of warts, and the warts on the plantar region are fused and about 11 cm.
And (3) clinical diagnosis: plantar warts.
The treatment method comprises the following steps: 5% of pentafluorouracil is singly used for scrubbing the affected part in 2016 (7 months and 23 days) until 8 months and 27 days, the effect is not good after one month of treatment, and the skin damage area is not obviously reduced. The treatment started on day 8/28: after the feet are cleaned, a bag of lotion is added with about 2000ml of warm water, the mixture is uniformly mixed and used for soaking the feet for 20-30 minutes, and after the mixture is wiped dry, 5% of pentafluorouracil is used for scrubbing the affected part once a day. One wart of about 1cm is left in the sole after 10 months and 3 days, the skin lesion is completely cured after 10 months and 15 days, and the skin lesion is completely recovered. After one year, no recurrence occurs after follow-up.
Case two:
guo in a certain age, male, age 42, administration of Shayangxian county.
Diagnosis and treatment time: 6 and 25 months in 2017.
The medical history: the left foot thumb of the patient is scattered in 3 warts, and the number of the warts is about 0.2-1.5 CM.
The treatment method comprises the following steps: the traditional Chinese medicine is soaked and washed for 15 days, once a day, and the skin damage disappears and the normal state is recovered after 15 days. After one year, no recurrence occurs after follow-up.
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and it is not intended that the invention be limited to these specific details. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Claims (6)
1. An external water aqua for treating plantar wart is characterized in that: the lotion A is prepared from pure traditional Chinese medicines and comprises the following raw material medicines:
lithospermum, raw coix seeds, isatis roots, lightyellow sophora roots, golden cypress, indigowoad leaves, safflower, nutgrass galingale rhizome, common scouring rush herbs, common cnidium fruits, cocklebur fruits and dahurian angelica roots.
2. The topical aqueous formulation for treating plantar warts as claimed in claim 1, wherein: the externally applied liquid B is a pentafluorouracil solution with the solubility of 5-10%.
3. The topical aqueous formulation for treating plantar warts as claimed in claim 2, wherein: the B external application water aqua is a pentafluorouracil solution with the solubility of 5%.
4. The topical aqueous formulation for treating plantar warts as claimed in claim 1, wherein: the lotion A comprises the following raw material medicaments in dosage:
20-50 parts of lithospermum, 30-70 parts of raw coix seeds, 30-70 parts of isatis roots, 10-30 parts of sophora flavescens, 10-30 parts of golden cypress, 30-70 parts of folium isatidis, 6-20 parts of safflower carthamus, 20-50 parts of rhizoma cyperi, 30-70 parts of equisetum hiemale, 15-40 parts of fructus cnidii, 15-40 parts of cocklebur fruits and 12-30 parts of angelica dahurica.
5. The topical aqueous formulation for treating plantar warts according to claim 4, wherein: the lotion A comprises the following raw material medicaments in dosage:
40 parts of lithospermum, 60 parts of raw coix seeds, 60 parts of isatis roots, 20 parts of sophora flavescens, 20 parts of golden cypress, 60 parts of folium isatidis, 12 parts of safflower, 40 parts of rhizoma cyperi, 60 parts of equisetum hiemale, 30 parts of fructus cnidii, 30 parts of cocklebur fruits and 24 parts of angelica dahurica.
6. The preparation method of the external water aqua for treating plantar wart as claimed in claims 1-5, comprising the following steps:
1) decocting: putting the raw materials into a special medicinal bag for decoction, soaking in clear water for 30 minutes, putting into a traditional Chinese medicine decocting machine, adding 1000ml of clear water, and decocting at 110 deg.C for 1 hr;
2) subpackaging: taking out the medicine bag after the decoction is finished, and subpackaging and plastic-sealing the decocted liquid medicine in the traditional Chinese medicine decocting machine according to 200 ml/bag.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911361356.7A CN110917307A (en) | 2019-12-26 | 2019-12-26 | External-use water aqua for treating verruca plantaris and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911361356.7A CN110917307A (en) | 2019-12-26 | 2019-12-26 | External-use water aqua for treating verruca plantaris and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110917307A true CN110917307A (en) | 2020-03-27 |
Family
ID=69862093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911361356.7A Pending CN110917307A (en) | 2019-12-26 | 2019-12-26 | External-use water aqua for treating verruca plantaris and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110917307A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114246926A (en) * | 2022-01-10 | 2022-03-29 | 上海中医药大学附属岳阳中西医结合医院 | External traditional Chinese medicine composition for treating skin warts and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107320679A (en) * | 2016-11-16 | 2017-11-07 | 河南省老足医医药科技有限公司 | The cream liquid double-formulation of plantar wart periungual wart is treated with the use of medicine and preparation method thereof |
-
2019
- 2019-12-26 CN CN201911361356.7A patent/CN110917307A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107320679A (en) * | 2016-11-16 | 2017-11-07 | 河南省老足医医药科技有限公司 | The cream liquid double-formulation of plantar wart periungual wart is treated with the use of medicine and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
王娣: "中西医结合治疗掌跖疣60例", 《中外医学研究》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114246926A (en) * | 2022-01-10 | 2022-03-29 | 上海中医药大学附属岳阳中西医结合医院 | External traditional Chinese medicine composition for treating skin warts and preparation method and application thereof |
CN114246926B (en) * | 2022-01-10 | 2022-12-06 | 上海中医药大学附属岳阳中西医结合医院 | External traditional Chinese medicine composition for treating skin warts and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100367985C (en) | Chinese prepared medicine for treating bone pain | |
CN102258658A (en) | Plaster for invigorating blood circulation and relieving pain | |
CN104258278A (en) | Gushangling (for bone injury) spray | |
CN103432551B (en) | Externally applied medicine for treating scapulohumeral periarthritis, radiohumeral bursitis and inexplicable ostalgia | |
CN102772712A (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
CN104383434A (en) | Externally applied medicament for treating traumatic injuries and rheumatism and preparation method of externally applied medicament | |
CN110917307A (en) | External-use water aqua for treating verruca plantaris and preparation method thereof | |
CN105194135A (en) | Hemorrhoids ointment, preparation method and application of hemorrhoids ointment | |
CN105106796A (en) | Traditional Chinese medicine composition for treating fracture and preparation method of traditional Chinese medicine composition | |
CN104043089A (en) | Medical biological dressing suppository for treating hemorrhoid | |
CN105250712B (en) | A kind of Chinese medicine composition for treating bedsore | |
CN107412491A (en) | A kind of externally applied ointment for treating hyperosteogeny patch and preparation method thereof | |
CN107802814A (en) | Chinese medicine composition and its manufactured plaster and preparation method | |
CN103142727B (en) | Chinese herbal medicine composition for treating burning and scalding of human body | |
CN104491183A (en) | Medicine used for treating burns and scalds | |
CN110772590A (en) | Chinese medicinal compound preparation for treating verruca plantaris | |
CN109529022A (en) | A kind of diabetic foot wound externally applied drug and its application method | |
CN113577166B (en) | Medicinal oil and preparation method thereof | |
CN109758565B (en) | Traditional Chinese medicine composition for externally treating spleen-stomach deficiency-cold type chronic gastritis by acupoint application and application thereof | |
CN105412395A (en) | Traditional Chinese medicine composition for treating hyperostosis and preparation method thereof | |
CN105560581A (en) | Traditional Chinese medicine tincture for treating chilblain and preparation method thereof | |
CN110013513A (en) | A kind of external-use gel and preparation method thereof for treating treating rheumatic ostealgia | |
CN105327290A (en) | Traditional Chinese medicine for external use for treating diabetic gangrene and preparation method thereof | |
CN104587353B (en) | A kind of medicine for treating scar | |
CN104758830A (en) | Traditional Chinese medicine composition for treating bone disease and skin injury and preparation method of traditional Chinese medicine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |
|
RJ01 | Rejection of invention patent application after publication |